MDSpire - Takeaway
From the Journals
Clinical Guidelines
Conference News

Evolocumab Reduced CV Events in Diabetes

Subgroup analysis of the VESALIUS-CV trial supports earlier intensive lipid lowering

Share

  • 1

    Evolocumab is a PCSK9 inhibitor evaluated for diabetes patients without significant atherosclerosis.

  • 2

    A total of 12,257 patients were enrolled across 774 sites in 33 countries.

  • 3

    Evolocumab lowered LDL cholesterol significantly compared to placebo.

  • 4

    A 41% reduction in major cardiovascular events was noted with evolocumab.

  • 5

    Serious adverse events were similar between evolocumab and placebo groups.

  • 6

    The study highlights the need for lower LDL-C targets in high-risk patients.

Original Source(s)

Evolocumab Reduced CV Events in Diabetes

  • by Kathryn Wighton

  • April 1, 2026

Related Content

Low-Dose Apixaban Cuts Superficial Thrombosis Risk

Extended anticoagulation lowered symptomatic superficial vein thrombosis in patients with provoked venous thromboembolism.

AGA May Signal Lipids, Female Obesity

Sex-stratified cohort links alopecia to hyperlipidemia in both sexes and obesity in females

Mediterranean Diet Linked to Higher Levels of Mitochondrial Microproteins

Greater adherence was associated with lower oxidative stress markers in older patients.